Form 4: Acrivon Therapeutics Executives Report Stock Transactions

Acrivon Therapeutics, Inc. executives Peter Blume-Jensen and Kristina Masson reported transactions related to their beneficial ownership of company stock.

Summary

• Peter Blume-Jensen, President and CEO and Director, reported the withholding of 13,729 shares of common stock to satisfy tax obligations upon the vesting of restricted stock units. This transaction occurred on May 21, 2026.
• Following this transaction, Peter Blume-Jensen directly beneficially owns 2,245,317 shares of common stock.
• Kristina Masson, EVP - Business Operations and Director, also reported transactions. The filing notes that she disclaims beneficial ownership of securities held by Peter Blume-Jensen, except to the extent of her pecuniary interest.
• Peter Blume-Jensen similarly disclaims beneficial ownership of securities held by Kristina Masson, except to the extent of his pecuniary interest.
• The filing indicates that Peter Blume-Jensen and Kristina Masson are spouses.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine administrative transactions related to executive compensation rather than significant strategic or financial events.

Positives

• Executives are actively involved with the company's stock, as indicated by their reporting of transactions.
• The withholding of shares for tax purposes upon vesting of RSUs is a standard and expected event for executive compensation.

Negatives

• The filing does not provide details on the market value or sale of the withheld shares, only that they were used to cover tax obligations.
• The disclaimer of beneficial ownership between spouses, while common, can sometimes add complexity to understanding true control of shares.

Risks

• The filing does not explicitly mention any risks.
• Potential future tax implications for executives related to stock vesting and withholding.

Future Outlook

This filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Management Comments

• Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
• Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, providing transparency into insider stock transactions. This filing is typical for executives managing their compensation packages and tax liabilities related to equity awards.

Related Party Transactions

• The filing notes that Peter Blume-Jensen and Kristina Masson are spouses, and each disclaims beneficial ownership of the other's securities except to the extent of their pecuniary interest.

Stakeholder Impact

• Shareholders gain transparency into insider stock transactions, which can inform their understanding of executive compensation and potential selling pressure.
• Employees may observe these transactions as part of the broader executive compensation framework.

Next Steps

• Continued reporting of insider transactions as they occur.
• Monitoring of future vesting and tax withholding events for executives.

Key Dates

Keywords

Form 4, SEC Filing, Acrivon Therapeutics, ACRV, Peter Blume-Jensen, Kristina Masson, Stock Transaction, Beneficial Ownership, Restricted Stock Units, Tax Withholding, Executive Compensation